News

A short-term rise in air pollution levels between neighboring days was significantly linked to an increased risk of schizophrenia hospitalizations in China.

Xanomeline trospium chloride offers a new pathway in schizophrenia treatment, improving cognitive symptoms without D2 receptor-related side effects like tardive dyskinesia.

Findings suggest obstetric complications are associated with more severe psychopathological phenotypes in schizophrenia and related disorders.

A study of more than 130k with schizophrenia revealed significant variability in relapse and treatment failure rates across different antipsychotics.

Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.

Based on the regulatory feedback provided by the FDA, Nanoscope announced plans to initiate Biologics License Application submission in Q1 2025.

The designation was granted to Mirum Pharmaceuticals based on a positive interim analysis of the phase 2b VANTAGE study of volixibat.

These data suggest that relapse among those with schizophrenia may be common 6 months after ECT, with more than half of patients likely to experience relapse within 2 years.

HCPLive spoke with Monroe regarding muscarinic modulators, both the ones in development and xanomeline trospium chloride capsules (Cobenfy).

Optimal use of GDMT therapy in heart failure could save an estimated 1.19 million lives globally over the course of 1 year.

During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such reactions.

Comorbid migraine and insomnia are linked to altered locus coeruleus connectivity, suggesting it is a biomarker for sleep disturbances and a potential therapeutic target.

Saggese explains the importance of second-line therapies in PBC, newly approved treatment options, and their impact on treatment goals and timelines.

New research reveals amyl nitrite (poppers) use is linked to dermatitis, with perianal and perioral regions most affected.

A meta-analysis shows that wet cupping reduces migraine intensity but doesn't improve quality of life. Adjunctive therapies offer limited additional benefits.

Topline results from the Phase 2b ODYSSEY trial show suprachoroidal CLS-AX achieved all primary and secondary outcomes for wet AMD.

These findings highlight the underrepresentation of Black and Hispanic food allergy clinical trial participants and raise concerns about the generalizability of clinical research findings.

Younossi explains how MASH negatively impacts patients’ quality of life and describes resmetirom’s benefit across multiple HRQoL domains.

BSC and Fresnius Kabi reached a deal facilitated by Evio Pharmacy Solutions by sidestepping pharmacy benefit managers.

New research presented at CHEST 2024 highlights ensifentrine’s effectiveness in improving lung function, symptoms, and quality of life for COPD patients, regardless of disease severity.

The FDA's decision to issue a CRL was announced on October 08, 2024 and cites issues with the timing of the facility inspection.

This September 2024 month in review highlights recent advances in gene therapies and therapies demonstrating the potential for improved vision outcomes.

HCPLive spoke with Maguire about the benefits of acetylcholine and muscarinic receptors for the treatment of schizophrenia.

This Month in Review article featured a variety of notable updates in the field of pulmonology covered in September 2024.

In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.

In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.

In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.

In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.